Caribou Biosciences (CRBU) Share-based Compensation (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Share-based Compensation data on file, last reported at $2.4 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.4 million, down 39.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.2 million (down 32.8% YoY), and the FY2025 annual result was $12.7 million, down 24.1% from the prior year.
• Share-based Compensation slipped to $2.4 million in Q1 2026 per CRBU's latest filing, from $2.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.7 million in Q2 2024 and troughed at $2.4 million in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.1 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2026: Share-based Compensation surged 781.63% in 2022, then sank 39.28% in 2026.
• A 5-year view of Share-based Compensation shows it stood at $3.1 million in 2022, then gained by 14.67% to $3.6 million in 2023, then climbed by 9.98% to $3.9 million in 2024, then retreated by 29.99% to $2.7 million in 2025, then decreased by 13.92% to $2.4 million in 2026.
• Business Quant data shows CRBU's Share-based Compensation at $2.4 million in Q1 2026, $2.7 million in Q4 2025, and $2.9 million in Q3 2025.